Electrochemical behaviour of anticancer drug Lomustine (cas 13010-47-4) and in situ evaluation of its interaction with DNA
-
Add time:08/28/2019 Source:sciencedirect.com
Electrochemical techniques were used to investigate the behavior of Lomustine (cas 13010-47-4) (CCNU) and its degradation in aqueous solution at a glassy carbon electrode (GCE). The in situ interaction of CCNU and chemically degraded CCNU (cdCCNU) with dsDNA was then investigated in dsDNA incubated solutions, using dsDNA electrochemical biosensors and comet assays. CCNU undergoes electrochemical reduction in two irreversible, diffusion-controlled, and pH-dependent redox processes, each with transfer of two electrons and one proton. At pH ≥ 10.1, the peak potential for the two processes was essentially pH-independent and involved only one electron. A mechanism was proposed for the reduction of CCNU in a neutral medium. In addition, it was found that CCNU underwent spontaneous degradation during incubation in aqueous solution, without the formation of electroactive degradation products. The degradation process was faster in basic media. Moreover, this pro-drug interacted with the DNA. Its metabolite(s) initially caused condensation of the double helix chains, followed by the unwinding of these chains. In addition, free guanine (Gua) was released from the dsDNA and oxidative damage to the DNA by the CCNU metabolite(s) was evidenced from the detection of 8-oxoGua and 2,8-oxoAde. These results were confirmed by the poly(dA)- and poly(dG)-polyhomonucleotide biosensors, which revealed the oxidative damage caused to both bases (guanine and adenine) of the dsDNA by the CCNU metabolite(s). The comet assay indicated breaks in the single strand DNA, complementing the results of the studies using differential pulse voltammetry. Conformational changes of dsDNA caused by CCNU and cdCCNU were confirmed using comet assays.
We also recommend Trading Suppliers and Manufacturers of Lomustine (cas 13010-47-4). Pls Click Website Link as below: cas 13010-47-4 suppliers
Prev:Inhibition by cadmium of thymidine metabolism in concanavalin A-activated murine splenocytes
Next:Lomustine (cas 13010-47-4)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- ArticlesSingle-agent bevacizumab or Lomustine (cas 13010-47-4) versus a combination of bevacizumab plus Lomustine (cas 13010-47-4) in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial09/04/2019
- Short communicationA stability-indicating liquid chromatographic method for Lomustine (cas 13010-47-4)09/03/2019
- ArticlesLomustine (cas 13010-47-4)-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial09/02/2019
- Original ArticleCombination toceranib and Lomustine (cas 13010-47-4) shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study09/01/2019
- Spectroscopic analysis of the interaction of Lomustine (cas 13010-47-4) with calf thymus DNA08/31/2019
- ArticlesRegorafenib compared with Lomustine (cas 13010-47-4) in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial08/30/2019
- Lomustine (cas 13010-47-4)08/29/2019